- Home
- COEP vs PLRX Comparison
COEP vs PLRX Comparison
Compare COEP & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- PLRX
- Stock Information
- Founded
- COEP 2017
- PLRX 2015
- Country
- COEP United States
- PLRX United States
- Employees
- COEP N/A
- PLRX N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- PLRX Health Care
- Exchange
- COEP Nasdaq
- PLRX Nasdaq
- Market Cap
- COEP 86.0M
- PLRX 93.3M
- IPO Year
- COEP N/A
- PLRX 2020
- Fundamental
- Price
- COEP $16.71
- PLRX $1.48
- Analyst Decision
- COEP
- PLRX Hold
- Analyst Count
- COEP 0
- PLRX 10
- Target Price
- COEP N/A
- PLRX $3.93
- AVG Volume (30 Days)
- COEP 63.6K
- PLRX 392.9K
- Earning Date
- COEP 11-12-2025
- PLRX 11-06-2025
- Dividend Yield
- COEP N/A
- PLRX N/A
- EPS Growth
- COEP N/A
- PLRX N/A
- EPS
- COEP N/A
- PLRX N/A
- Revenue
- COEP $263,555.00
- PLRX N/A
- Revenue This Year
- COEP N/A
- PLRX N/A
- Revenue Next Year
- COEP N/A
- PLRX N/A
- P/E Ratio
- COEP N/A
- PLRX N/A
- Revenue Growth
- COEP N/A
- PLRX N/A
- 52 Week Low
- COEP $2.31
- PLRX $1.10
- 52 Week High
- COEP $19.19
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- COEP 58.33
- PLRX 48.09
- Support Level
- COEP $16.00
- PLRX $1.42
- Resistance Level
- COEP $18.15
- PLRX $1.55
- Average True Range (ATR)
- COEP 1.60
- PLRX 0.08
- MACD
- COEP 0.05
- PLRX -0.00
- Stochastic Oscillator
- COEP 61.02
- PLRX 57.93
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.